Top

11-04-2016 | Giant cell arteritis | Review | Article

Update on the Epidemiology and Treatment of Giant Cell Arteritis

Journal: Current Treatment Options in Rheumatology

Authors: Matthew J. Koster, MD, Kenneth J. Warrington, MD, Tanaz A. Kermani, MD, MS

Publisher: Springer International Publishing

Abstract

Giant cell arteritis is the most common form of primary systemic vasculitis in people over the age of 50 years. This disease affects the aorta and its branches, and complications may include vision loss, arterial stenosis, and aortic aneurysm. Early recognition and treatment of giant cell arteritis is important to mitigate long-term damage. While glucocorticoids remain the mainstay of treatment, relapses are common and morbidity related to treatment frequently occurs. There is an unmet need for immunosuppressive therapies that are able to induce long-term remission while avoiding the adverse effects of glucocorticoids. Of available conventional immunosuppressive treatments, methotrexate is generally considered a first-line steroid-sparing agent for patients with disease refractory to glucocorticoids and in those at high risk for glucocorticoid-associated toxicity. Advances in understanding of disease pathogenesis continue to identify potential therapeutic targets, and several biologic agents are currently under investigation. Preliminary reports from controlled studies demonstrate potential efficacy of tocilizumab and abatacept in both newly diagnosed and relapsing patients; however, use of these agents should not yet be considered standard therapy. The role of anti-platelet therapy in prevention of ischemic complications is controversial, but low-dose aspirin is considered reasonable in this population. Statin medications have little role in the management of giant cell arteritis (GCA) and should be reserved for those with clinical indications for lipid reduction. Correction of arterial stenosis with surgical revascularization is uncommonly required for patients with refractory ischemic symptoms. Intervention should be performed in patients with quiescent disease. Monitoring for late-onset complications, particularly thoracic aortic aneurysm, should take place though the frequency of screening and the optimal timing of intervention is not established.

1.•

Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1–11. This publication includes an international consensus statement on the names and definitions of systemic vasculitis. In addition to updates on suggested classification of vasculitis (expands on the previous classification by vessel size), updated nomenclature is also addressed.PubMedCrossRef

2.••

Muratore F, Kermani TA, Crowson CS, Green AB, Salvarani C, Matteson EL, et al. Large-vessel giant cell arteritis: a cohort study. Rheumatology (Oxford). 2015;54(3):463–70. Largest single-center study evaluating the treatment and outcomes of patients with giant cell arteritis and upper extremity arterial involvement. The study found differences in the baseline characteristics and prognosis of these patients.PubMedCentralCrossRef

Weyand CM, Goronzy JJ. Clinical practice. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med. 2014;371(1):50–7.PubMedPubMedCentralCrossRef

4.•

Kermani TA, Warrington KJ, Crowson CS, Ytterberg SR, Hunder GG, Gabriel SE, et al. Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis. Ann Rheum Dis. 2013;72(12):1989–94. Population-based study evaluating large-vessel complications in patients with giant cell arteritis and the long-term outcome including increased mortality in subjects with aortic manifestations.PubMedPubMedCentralCrossRef

5.•

Labarca C, Koster MJ, Crowson CS, Makol A, Ytterberg SR, Matteson EL, et al. Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study. Rheumatology (Oxford). 2015 Sep 18 [E-pub]. Largest North American single center cohort evaluating glucocorticoid use and outcomes among biopsy-proven patients with giant cell arteritis. Patients with higher initial prednisone doses were able to taper and discontinue steroids sooner without increased risk of associated adverse events

Alba MA, Garcia-Martinez A, Prieto-Gonzalez S, Tavera-Bahillo I, Corbera-Bellalta M, Planas-Rigol E, et al. Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. Medicine (Baltimore). 2014;93(5):194–201.CrossRef

7.••

Carmona FD, Mackie SL, Martin JE, Taylor JC, Vaglio A, Eyre S, et al. A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility. Am J Hum Genet. 2015;96(4):565–80. The findings of a large, multicenter study of the genetic susceptibility in patients with giant cell arteritis. The study confirms prior reports of the association of HLA class II alleles in addition to novel findings of other non-HLA alleles which may provide insight into the pathophysiology of giant cell arteritis.PubMedPubMedCentralCrossRef

Blockmans D, de Ceuninck L, Vanderschueren S, Knockaert D, Mortelmans L, Bobbaers H. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum. 2006;55(1):131–7.PubMedCrossRef

Chandran AK, Udayakumar PD, Crowson CS, Warrington KJ, Matteson EL. The incidence of giant cell arteritis in Olmsted County, Minnesota, over a 60-year period 1950-2009. Scand J Rheumatol. 2015;44(3):215–8.PubMedPubMedCentralCrossRef

10.

Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, Miranda-Filloy JA, Gonzalez-Juanatey C, Martin J, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 2009;61(10):1454–61.PubMedCrossRef

11.

Smetana GW, Shmerling RH. Does this patient have temporal arteritis? Jama. 2002;287(1):92–101.PubMedCrossRef

12.

Salvarani C, Crowson CS, O’Fallon WM, Hunder GG, Gabriel SE. Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. Arthritis Rheum. 2004;51(2):264–8.PubMedCrossRef

13.

Mohammad AJ, Nilsson JA, Jacobsson LT, Merkel PA, Turesson C. Incidence and mortality rates of biopsy-proven giant cell arteritis in southern Sweden. Ann Rheum Dis. 2015;74(6):993–7.PubMedCrossRef

14.•

Dunstan E, Lester SL, Rischmueller M, Dodd T, Black R, Ahern M, et al. Epidemiology of biopsy-proven giant cell arteritis in South Australia. Intern Med J. 2014;44(1):32–9. First published study providing us data with epidemiology of giant cell arteritis in Australia.PubMedCrossRef

15.

Gonzalez-Gay MA, Miranda-Filloy JA, Lopez-Diaz MJ, Perez-Alvarez R, Gonzalez-Juanatey C, Sanchez-Andrade A, et al. Giant cell arteritis in northwestern Spain: a 25-year epidemiologic study. Medicine (Baltimore). 2007;86(2):61–8.CrossRef

16.

Nordborg C, Johansson H, Petursdottir V, Nordborg E. The epidemiology of biopsy-positive giant cell arteritis: special reference to changes in the age of the population. Rheumatology (Oxford). 2003;42(4):549–52.CrossRef

17.

Nesher G, Gur H, Ehrenfeld M, Rubinow A, Sonnenblick M. The changing clinical presentation of temporal arteritis in Israel: a multicenter study. Isr Med Assoc J. 1999;1(1):17–9.PubMed

18.

Kermani TA, Schafer VS, Crowson CS, Hunder GG, Gabriel SE, Matteson EL, et al. Increase in age at onset of giant cell arteritis: a population-based study. Ann Rheum Dis. 2010;69(4):780–1.PubMedCrossRef

19.

Boesen P, Sorensen SF. Giant cell arteritis, temporal arteritis, and polymyalgia rheumatica in a Danish county. A prospective investigation, 1982-1985. Arthritis Rheum. 1987;30(3):294–9.PubMedCrossRef

20.

Gran JT, Myklebust G. The incidence of polymyalgia rheumatica and temporal arteritis in the county of Aust Agder, south Norway: a prospective study 1987-94. J Rheumatol. 1997;24(9):1739–43.PubMed

21.

Haugeberg G, Paulsen PQ, Bie RB. Temporal arteritis in Vest Agder County in southern Norway: incidence and clinical findings. J Rheumatol. 2000;27(11):2624–7.PubMed

22.

Nordborg E, Bengtsson BA. Epidemiology of biopsy-proven giant cell arteritis (GCA). J Intern Med. 1990;227(4):233–6.PubMedCrossRef

23.

Bengtsson BA, Malmvall BE. The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. Incidences of different clinical presentations and eye complications. Arthritis Rheum. 1981;24(7):899–904.PubMedCrossRef

24.

Baldursson O, Steinsson K, Bjornsson J, Lie JT. Giant cell arteritis in Iceland. An epidemiologic and histopathologic analysis. Arthritis Rheum. 1994;37(7):1007–12.PubMedCrossRef

25.

Petursdottir V, Johansson H, Nordborg E, Nordborg C. The epidemiology of biopsy-positive giant cell arteritis: special reference to cyclic fluctuations. Rheumatology (Oxford). 1999;38(12):1208–12.CrossRef

26.

Petri H, Nevitt A, Sarsour K, Napalkov P, Collinson N. Incidence of giant cell arteritis and characteristics of patients: data-driven analysis of comorbidities. Arthritis Care Res (Hoboken). 2015;67(3):390–5.CrossRef

27.

Romero-Gomez C, Aguilar-Garcia JA, Garcia-de-Lucas MD, Cotos-Canca R, Olalla-Sierra J, Garcia-Alegria JJ, et al. Epidemiological study of primary systemic vasculitides among adults in southern Spain and review of the main epidemiological studies. Clin Exp Rheumatol. 2015;33(2 Suppl 89):S-11-8.PubMed

28.

Salvarani C, Gabriel SE, O’Fallon WM, Hunder GG. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med. 1995;123(3):192–4.PubMedCrossRef

29.

Reinhold-Keller E, Zeidler A, Gutfleisch J, Peter HH, Raspe HH, Gross WL. Giant cell arteritis is more prevalent in urban than in rural populations: results of an epidemiological study of primary systemic vasculitides in Germany. Rheumatology (Oxford). 2000;39(12):1396–402.CrossRef

30.

Smeeth L, Cook C, Hall AJ. Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990-2001. Ann Rheum Dis. 2006;65(8):1093–8.PubMedPubMedCentralCrossRef

31.

Smith CA, Fidler WJ, Pinals RS. The epidemiology of giant cell arteritis. Report of a ten-year study in Shelby County, Tennessee. Arthritis Rheum. 1983;26(10):1214–9.PubMedCrossRef

32.

Ramstead CL, Patel AD. Giant cell arteritis in a neuro-ophthalmology clinic in Saskatoon, 1998-2003. Can J Ophthalmol. 2007;42(2):295–8.PubMed

33.

Mader TH, Werner RP, Chamberlain DG, Doornbos D. Giant cell arteritis in Alaska Natives. Can J Ophthalmol. 2009;44(1):53–6.PubMedCrossRef

34.

Pereira LS, Yoon MK, Hwang TN, Hong JE, Ray K, Porco T, et al. Giant cell arteritis in Asians: a comparative study. Br J Ophthalmol. 2011;95(2):214–6.PubMedCrossRef

35.

Guerra A, Magraner M, Serrano L, Bredy R. Temporal arteritis in Puerto Rico Hispanics. Bol Asoc Med P R. 2006;98(4):304–11.PubMed

36.

Lam BL, Wirthlin RS, Gonzalez A, Dubovy SR, Feuer WJ. Giant cell arteritis among Hispanic Americans. Am J Ophthalmol. 2007;143(1):161–3.PubMedPubMedCentralCrossRef

37.

Alba MA, Mena-Madrazo JA, Reyes E, Flores-Suarez LF. Giant cell arteritis in Mexican patients. J Clin Rheumatol. 2012;18(1):1–7.PubMedCrossRef

38.•

Abdul-Rahman AM, Molteno AC, Bevin TH. The epidemiology of giant cell arteritis in Otago, New Zealand: a 9-year analysis. N Z Med J. 2011;124(1329):44–52. First publication which provides us with data on the epidemiology of giant cell arteritis in New Zealand.PubMed

39.

Bas-Lando M, Breuer GS, Berkun Y, Mates M, Sonnenblick M, Nesher G. The incidence of giant cell arteritis in Jerusalem over a 25-year period: annual and seasonal fluctuations. Clin Exp Rheumatol. 2007;25(1 Suppl 44):S15–7.PubMed

40.

Pamuk ON, Donmez S, Karahan B, Pamuk GE, Cakir N. Giant cell arteritis and polymyalgia rheumatica in northwestern Turkey: clinical features and epidemiological data. Clin Exp Rheumatol. 2009;27(5):830–3.PubMed

41.

Kobayashi S, Yano T, Matsumoto Y, Numano F, Nakajima N, Yasuda K, et al. Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: the first government-supported nationwide survey. Arthritis Rheum. 2003;49(4):594–8.PubMedCrossRef

42.

Singh S, Balakrishnan C, Mangat G, Samant R, Bambani M, Kalke S, et al. Giant cell arteritis in Mumbai. J Assoc Physicians India. 2010;58:372–4.PubMed

43.

Chaudhry IA, Shamsi FA, Elzaridi E, Arat YO, Bosley TM, Riley FC. Epidemiology of giant-cell arteritis in an Arab population: a 22-year study. Br J Ophthalmol. 2007;91(6):715–8.PubMedPubMedCentralCrossRef

44.

Khalifa M, Karmani M, Jaafoura NG, Kaabia N, Letaief AO, Bahri F. Epidemiological and clinical features of giant cell arteritis in Tunisia. Eur J Intern Med. 2009;20(2):208–12.PubMedCrossRef

45.••

Carmona FD, Gonzalez-Gay MA, Martin J. Genetic component of giant cell arteritis. Rheumatology (Oxford). 2014;53(1):6–18. Excellent and comprehensive review article on the genetics of giant cell arteritis.CrossRef

46.•

Serrano A, Marquez A, Mackie SL, Carmona FD, Solans R, Miranda-Filloy JA, et al. Identification of the PTPN22 functional variant R620W as susceptibility genetic factor for giant cell arteritis. Ann Rheum Dis. 2013;72(11):1882–6. Recent publication on the genetic susceptibility of giant cell arteritis which found that polymorphissm in PTPN22 which has been associated with susceptibility to other autoimmune diseases may also play a role in giant cell arteritis.PubMedPubMedCentralCrossRef

47.•

Marquez A, Hernandez-Rodriguez J, Cid MC, Solans R, Castaneda S, Fernandez-Contreras ME, et al. Influence of the IL17A locus in giant cell arteritis susceptibility. Ann Rheum Dis. 2014;73(9):1742–5. Study which found polymorphisms in IL17A may confer susceptibility to giant cell arteritis keeping with other reports which have shown IL-17 plays a role in the pathogenesis of this disease.PubMedCrossRef

48.

Kisza K, Murchison AP, Dai Y, Bilyk JR, Eagle Jr RC, Sergott R, et al. Giant cell arteritis incidence: analysis by season and year in mid-Atlantic United States. Clin Experiment Ophthalmol. 2013;41(6):577–81.PubMedCrossRef

49.

Sonnenblick M, Nesher G, Friedlander Y, Rubinow A. Giant cell arteritis in Jerusalem: a 12-year epidemiological study. Br J Rheumatol. 1994;33(10):938–41.PubMedCrossRef

50.•

Gilden D, White T, Khmeleva N, Heintzman A, Choe A, Boyer PJ, et al. Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis. Neurology. 2015;84(19):1948–55. This study provides data that varicella zoster virus may play a role in the pathogenesis ofs giant cell arteritis.PubMedCrossRef

51.

Mackie SL, Dasgupta B, Hordon L, Gough A, Green M, Hollywood J, et al. Ischaemic manifestations in giant cell arteritis are associated with area level socio-economic deprivation, but not cardiovascular risk factors. Rheumatology (Oxford). 2011;50(11):2014–22.CrossRef

52.

Zoller B, Li X, Sundquist J, Sundquist K. Occupational and socio-economic risk factors for giant cell arteritis: a nationwide study based on hospitalizations in Sweden. Scand J Rheumatol. 2013;42(6):487–97.PubMedCrossRef

53.

Dasgupta B, Borg FA, Hassan N, Alexander L, Barraclough K, Bourke B, et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 2010;49(8):1594–7.CrossRef

54.

Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2009;68(3):318–23.PubMedCrossRef

55.

Hunder GG, Sheps SG, Allen GL, Joyce JW. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Ann Intern Med. 1975;82(5):613–8.PubMedCrossRef

56.

Mazlumzadeh M, Hunder GG, Easley KA, Calamia KT, Matteson EL, Griffing WL, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 2006;54(10):3310–8.PubMedCrossRef

57.

Chevalet P, Barrier JH, Pottier P, Magadur-Joly G, Pottier MA, Hamidou M, et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol. 2000;27(6):1484–91.PubMed

58.

Lundberg I, Hedfors E. Restricted dose and duration of corticosteroid treatment in patients with polymyalgia rheumatica and temporal arteritis. J Rheumatol. 1990;17(10):1340–5.PubMed

59.

Nesher G, Rubinow A, Sonnenblick M. Efficacy and adverse effects of different corticosteroid dose regimens in temporal arteritis: a retrospective study. Clin Exp Rheumatol. 1997;15(3):303–6.PubMed

60.

Delecoeuillerie G, Joly P, Cohen de Lara A, Paolaggi JB. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). Ann Rheum Dis. 1988;47(9):733–9.PubMedPubMedCentralCrossRef

61.

Les I, Pijoan JI, Rodriguez-Alvarez R, Ruiz-Irastorza G, Martinez-Berriotxoa A. Effectiveness and safety of medium-dose prednisone in giant cell arteritis: a retrospective cohort study of 103 patients. Clin Exp Rheumatol. 2015;33(2 Suppl 89):S-90-7.PubMed

62.••

Weyand CM, Goronzy JJ. Immune mechanisms in medium and large-vessel vasculitis. Nat Rev Rheumatol. 2013;9(12):731–40. Comprehensive review article outlining the cellular pathways and cytokines involved in the pathogenesis of giant cell arteritis.PubMedPubMedCentralCrossRef

63.

Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation. 2010;121(7):906–15.PubMedPubMedCentralCrossRef

64.

Fritzlen J, Younge BR, Weyand CM, Hunder GG, Warrington KJ, Maleszewski J. Second temporal artery biopsies in patients with temporal arteritis. Arthritis Rheumatol. 2015;67:(suppl 10).

65.

Spiera RF, Mitnick HJ, Kupersmith M, Richmond M, Spiera H, Peterson MG, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol. 2001;19(5):495–501.PubMed

66.

Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Banares A, Fernandez-Gutierrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134(2):106–14.PubMedCrossRef

67.

Hoffman GS, Cid MC, Hellmann DB, Guillevin L, Stone JH, Schousboe J, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002;46(5):1309–18.PubMedCrossRef

68.

Mahr AD, Jover JA, Spiera RF, Hernandez-Garcia C, Fernandez-Gutierrez B, Lavalley MP, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2007;56(8):2789–97.PubMedCrossRef

69.

Quartuccio L, Maset M, De Maglio G, Pontarini E, Fabris M, Mansutti E, et al. Role of oral cyclophosphamide in the treatment of giant cell arteritis. Rheumatology (Oxford). 2012;51(9):1677–86.CrossRef

70.

Loock J, Henes J, Kotter I, Witte T, Lamprecht P, Schirmer M, et al. Treatment of refractory giant cell arteritis with cyclophosphamide:a retrospective analysis of 35 patients from three centres. Clin Exp Rheumatol. 2012;30(1 Suppl 70):S70–6.PubMed

71.

Henes JC, Mueller M, Pfannenberg C, Kanz L, Koetter I. Cyclophosphamide for large vessel vasculitis: assessment of response by PET/CT. Clin Exp Rheumatol. 2011;29(1 Suppl 64):S43–8.PubMed

72.•

de Boysson H, Boutemy J, Creveuil C, Ollivier Y, Letellier P, Pagnoux C, et al. Is there a place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review. Semin Arthritis Rheum. 2013;43(1):105–12. This systematic review comprehensively outlines the available information regarding the use of cyclophosphamide in giant cell arteritis.PubMedCrossRef

73.

Diamantopoulos AP, Hetland H, Myklebust G. Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series. Biomed Res Int. 2013;2013:120638.PubMedPubMedCentralCrossRef

74.

Adizie T, Christidis D, Dharmapaliah C, Borg F, Dasgupta B. Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series. Int J Clin Pract. 2012;66(9):906–9.PubMedCrossRef

75.

De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis. 1986;45(2):136–8.PubMedPubMedCentralCrossRef

76.

Sciascia S, Piras D, Baldovino S, Russo A, Naretto C, Rossi D, et al. Mycophenolate mofetil as steroid-sparing treatment for elderly patients with giant cell arteritis: report of three cases. Aging Clin Exp Res. 2012;24(3):273–7.PubMedCrossRef

77.

Goel R, Danda D, Mathew J, Edwin N. Mycophenolate mofetil in Takayasu’s arteritis. Clin Rheumatol. 2010;29(3):329–32.PubMedCrossRef

78.

Hernandez-Rodriguez J, Segarra M, Vilardell C, Sanchez M, Garcia-Martinez A, Esteban MJ, et al. Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford). 2004;43(3):294–301.CrossRef

79.•

Samson M, Audia S, Janikashvili N, Bonnotte B. Is TNF-alpha really involved in giant cell arteritis pathogenesis? Ann Rheum Dis. 2014;73(1):e1. This brief report challenges the role of TNF-alpha in giant cell arteritis by demonstrating a lack of increase among patients with active disease compared to controls.PubMedCrossRef

80.

Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007;146(9):621–30.PubMedCrossRef

81.

Martinez-Taboada VM, Rodriguez-Valverde V, Carreno L, Lopez-Longo J, Figueroa M, Belzunegui J, et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis. 2008;67(5):625–30.PubMedCrossRef

82.

Seror R, Baron G, Hachulla E, Debandt M, Larroche C, Puechal X, et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Ann Rheum Dis. 2014;73(12):2074–81.PubMedCrossRef

83.

Adler S, Reichenbach S, Kuchen S, Wermelinger F, Dan D, PM. V, et al. Tocilizumab for the treatment of giant cell arteritis—a randomized placebo-controlled trial. Arthritis Rheumatol. 2015;67:(suppl 10).

84.

Langford C, Cuthbertson D, Ytterberg S, Khalidi N, Monach P, Carette S, et al. A randomized double-blind trial of abatacept and glucocorticoids for the treatment of giant cell arteritis. Arthritis Rheumatol. 2015;67:(suppl 10).

85.

Ly KH, Stirnemann J, Liozon E, Michel M, Fain O, Fauchais AL. Interleukin-1 blockade in refractory giant cell arteritis. Joint Bone Spine. 2014;81(1):76–8.PubMedCrossRef

86.

Conway R, O’Neill L, O’Flynn E, McCarthy G, Murphy C, Veale D, et al. Ustekinumab for the treatment of refractory giant cell arteritis Arthritis Rheumatol. 2015;67:(suppl 10).

87.

Mayrbaeurl B, Hinterreiter M, Burgstaller S, Windpessl M, Thaler J. The first case of a patient with neutropenia and giant-cell arteritis treated with rituximab. Clin Rheumatol. 2007;26(9):1597–8.PubMedCrossRef

88.

Bhatia A, Ell PJ, Edwards JC. Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis. 2005;64(7):1099–100.PubMedPubMedCentralCrossRef

89.

Weyand CM, Kaiser M, Yang H, Younge B, Goronzy JJ. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis Rheum. 2002;46(2):457–66.PubMedCrossRef

90.

Lee MS, Smith SD, Galor A, Hoffman GS. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum. 2006;54(10):3306–9.PubMedCrossRef

91.

Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, Sonnenblick M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 2004;50(4):1332–7.PubMedCrossRef

92.

Gonzalez-Gay MA, Pineiro A, Gomez-Gigirey A, Garcia-Porrua C, Pego-Reigosa R, Dierssen-Sotos T, et al. Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine (Baltimore). 2004;83(6):342–7.CrossRef

93.

Narvaez J, Bernad B, Gomez-Vaquero C, Garcia-Gomez C, Roig-Vilaseca D, Juanola X, et al. Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. Clin Exp Rheumatol. 2008;26(3 Suppl 49):S57–62.PubMed

94.

Salvarani C, Della Bella C, Cimino L, Macchioni P, Formisano D, Bajocchi G, et al. Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology (Oxford). 2009;48(3):250–3.CrossRef

95.••

Martinez-Taboada VM, Lopez-Hoyos M, Narvaez J, Munoz-Cacho P. Effect of antiplatelet/anticoagulant therapy on severe ischemic complications in patients with giant cell arteritis: a cumulative meta-analysis. Autoimmun Rev. 2014;13(8):788–94. Excellent and comprehensive meta-analsysis evaluating the benefit of anti-platelet therapy in patient with giant cell arteritis.PubMedCrossRef

96.

Souza AW, Okamoto KY, Abrantes F, Schau B, Bacchiega AB, Shinjo SK. Giant cell arteritis: a multicenter observational study in Brazil. Clinics (Sao Paulo). 2013;68(3):317–22.CrossRef

97.

Satoh M, Takahashi Y, Tabuchi T, Minami Y, Tamada M, Takahashi K, et al. Cellular and molecular mechanisms of statins: an update on pleiotropic effects. Clin Sci (Lond). 2015;129(2):93–105.CrossRef

98.

Schmidt J, Kermani TA, Muratore F, Crowson CS, Matteson EL, Warrington KJ. Statin use in giant cell arteritis: a retrospective study. J Rheumatol. 2013;40(6):910–5.PubMedPubMedCentralCrossRef

99.•

Pugnet G, Sailler L, Bourrel R, Montastruc JL, Lapeyre-Mestre M. Is statin exposure associated with occurrence or better outcome in giant cell arteritis? Results from a French population-based study. J Rheumatol. 2015;42(2):316–22. This large population-based study evaluating the role of statin therapy in giant cell arteritis found no association with this medication and disease occurrence and minimal benefit in corticosteroid tapering.PubMedCrossRef

100.

Narvaez J, Bernad B, Nolla JM, Valverde J. Statin therapy does not seem to benefit giant cell arteritis. Semin Arthritis Rheum. 2007;36(5):322–7.PubMedCrossRef

101.

Garcia-Martinez A, Hernandez-Rodriguez J, Grau JM, Cid MC. Treatment with statins does not exhibit a clinically relevant corticosteroid-sparing effect in patients with giant cell arteritis. Arthritis Rheum. 2004;51(4):674–8.PubMedCrossRef

102.

Ostberg G. Temporal arteritis in a large necropsy series. Ann Rheum Dis. 1971;30(3):224–35.PubMedPubMedCentralCrossRef

103.

Ostberg G. An arteritis with special reference to polymyalgia arteritica. Acta Pathol Microbiol Scand Suppl. 1973;237 Suppl 237:1–59.PubMed

104.

Czihal M, Piller A, Schroettle A, Kuhlencordt PJ, Schulze-Koops H, Hoffmann U. Outcome of giant cell arteritis of the arm arteries managed with medical treatment alone: cross-sectional follow-up study. Rheumatology (Oxford). 2013;52(2):282–6.CrossRef

105.

Kermani TA, Matteson EL, Hunder GG, Warrington KJ. Symptomatic lower extremity vasculitis in giant cell arteritis: a case series. J Rheumatol. 2009;36(10):2277–83.PubMedCrossRef

106.

Assie C, Janvresse A, Plissonnier D, Levesque H, Marie I. Long-term follow-up of upper and lower extremity vasculitis related to giant cell arteritis: a series of 36 patients. Medicine (Baltimore). 2011;90(1):40–51.CrossRef

107.

Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(41):2873–926.PubMedCrossRef

Medicine Matters Rheumatology

Abstract